COMMUNIQUÉS West-GlobeNewswire

STRATA Skin Sciences Announces Closing of $2.42 Million Registered Direct Offering
04/09/2025
HORSHAM, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (Nasdaq: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative [...]
Silent Killer: HTLV 2026 Conference Launches Global Campaign to Fight HIV’s “Cousin” Virus Infecting Millions
04/09/2025
Scientist Spearheads Global Initiative to Raise Awareness and Combat HTLV-1, a Lesser-Known Retrovirus Causing Deadly Cancer with No Current Cure or Vaccine Philadelphia, PA , Sept. 04, 2025 (GLOBE NEWSWIRE) -- HTLV [...]
Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension
04/09/2025
Another addition to Amneal’s growing complex injectables portfolio reflects leadership in advanced development and manufacturing of complex pharmaceuticals BRIDGEWATER, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Amneal [...]
Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
04/09/2025
RADNOR, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities [...]
Indaptus Therapeutics Provides Clinical Update
04/09/2025
Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastases Decoy20 combination with PD-1 inhibitor, tislelizumab, demonstrates safety profiles consistent with each agent NEW YORK [...]
Praxis Precision Medicines to Participate in September Investor Conferences
04/09/2025
BOSTON, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central [...]
Inventiva to Participate in Upcoming September Investor Conferences
04/09/2025
Daix (France), New York City (New York, United States), September 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the [...]
Inventiva annonce sa participation à plusieurs conférences investisseurs en septembre
04/09/2025
Daix (France), New York City (New York, Etats-Unis), le 4 septembre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de [...]
Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas
04/09/2025
The risk adjusted Net Present Value (rNPV) for TVGN 930 is estimated to exceed ~$250 million in the US alone. Covering five rare disease eligible indications, the accessible market in the US could be as high as 40,000 [...]
What’s Really Going On With Federal Funding? SMI and Travis Taylor Lead iC³® Summit Panel Discussion to Deliver Clarity in a Volatile Policy Era
04/09/2025
DALLAS, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Institutions, and organizations across the life sciences continuum are seeking clarity on how federal research and development (R&D) funding and critical resources can be [...]
Rapafusyn Pharmaceuticals Closes Over-Subscribed $44 Million Series A Financing to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform
04/09/2025
BioTrack Capital and Yonjin Capital join Series A round alongside other investors including 3E Bioventures Capital, Proxima Ventures Ltd., and Lapam Capital Upsized and over-subscribed Series A total funding of $44 [...]
The Ninth Circuit Orders California to Respond concerning its Mandatory DEI Indoctrination in Continuing Medical Education Courses, According to the Association of American Physicians and Surgeons
04/09/2025
TUCSON, Ariz., Sept. 04, 2025 (GLOBE NEWSWIRE) -- On September 2, the U.S. Court of Appeals for the Ninth Circuit ordered California to respond to a petition for rehearing challenging its diversity, equity, and [...]
Avania Strengthens Leadership Team with Appointment of Four New Executives
04/09/2025
BILTHOVEN, Netherlands and BOSTON, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Avania , the leading global MedTech advisory and clinical development partner, is pleased to announce strategic leadership appointments of four [...]
Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025
04/09/2025
ZUG, Switzerland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with [...]
Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025
04/09/2025
ZUG, Switzerland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with [...]
Reverse Stock Split Strengthens HealthLynked’s Market Position as Company Scales AI-Driven Healthcare Platform
04/09/2025
NAPLES, Fla., Sept. 04, 2025 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. (OTCQB: HLYK ) -- Dear Shareholders, I'm writing to share an important update in the continued evolution of HealthLynked Corp. that reflects [...]
OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation
04/09/2025
OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation NANTES, France – September 4, 2025, 6 p.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) [...]
OSE Immunotherapeutics : une stratégie claire, une gouvernance équilibrée, un cap affirmé vers la création de valeur
04/09/2025
OSE Immunotherapeutics : une stratégie claire, une gouvernance équilibrée, un cap affirmé vers la création de valeur NANTES, France – 4 septembre 2025, 6 p.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: [...]
OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation
04/09/2025
OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation NANTES, France – September 4, 2025, 6 p.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) [...]

Pages